Background: Mutations in the p53 tumor suppressor gene (also known as TP53) have been detected in a wide variety of human cancers. In breast cancer, the presence of p53 gene alterations has been associated with worse prognosis. Purpose: We compared a complementary DNA (cDNA)-based sequencing method and an immunohistochemical (IHC) method for their abilities to detect p53 mutations in breast cancer specimens. In addition, we determined the prognostic value of information obtained when these two methods were used. Methods: Specimens from 316 primary breast tumors were evaluated for the presence of mutant p53 protein by use of the mouse monoclonal antibody Pab 1801 (that recognizes both wild-type and mutant forms of p53) and standard IHC methods. In addition, the entire coding region of p53 genes expressed in these tumors was screened for mutations by combining reverse transcription, the polymerase chain reaction, and DNA sequencing. Probabilities for overall survival (OS), breast cancer-corrected survival (BCCS; death from breast cancer is the considered event), and relapse-free survival (RFS) were estimated by use of the Kaplan-Meier method, and survival curves for different patient subgroups were compared by use of the logrank method. All reported P values are from two-sided tests. Results: Sixty-nine (22%) of 316 tumors had p53 gene mutations detected by the cDNAbased sequencing method; only 31 (45%) of these mutations were located in evolutionary conserved portions of the p53 coding region. Sixty-four tumors (20% of the total) had elevated levels of p53 protein as detected by IHC, suggesting the presence of mutations. Of the sequencing-positive tumors (i.e., p53 mutant), 23 exhibited negative IHC reactions, indicating that IHC failed to detect 33% of the mutations. Furthermore, 19 of the IHC-positive tumors were sequencing negative (i.e., p53 wild-type), suggesting a 30% false-positive frequency with IHC. Four tumors (1.3% of the total) could not be analyzed by the cDNA-based sequencing method, and three tumors (1% of the total) could not be analyzed by IHC. The 5-year estimates for RFS, BCCS, and
Background: Mutations in the p53 tumor suppressor gene (also known as TP53) have been detected in a wide variety of human cancers. In breast cancer, the presence of p53 gene alterations has been associated with worse prognosis. Purpose: We compared a complementary DNA (cDNA)-based sequencing method and an immunohistochemical (IHC) method for their abilities to detect p53 mutations in breast cancer specimens. In addition, we determined the prognostic value of information obtained when these two methods were used. Methods: Specimens from 316 primary breast tumors were evaluated for the presence of mutant p53 protein by use of the mouse monoclonal antibody Pab 1801 (that recognizes both wild-type and mutant forms of p53) and standard IHC methods. In addition, the entire coding region of p53 genes expressed in these tumors was screened for mutations by combining reverse transcription, the polymerase chain reaction, and DNA sequencing. Probabilities for overall survival (OS), breast cancer-corrected survival (BCCS; death from breast cancer is the considered event), and relapse-free survival (RFS) were estimated by use of the Kaplan-Meier method, and survival curves for different patient subgroups were compared by use of the logrank method. Alteration of the tumor suppressor gene p53 (also known as TP53) is considered to be a critical step in the development of many human cancers (1,2). Changes in this gene have been detected in a wide range of human tumors, including breast cancers (3). The p53 gene is located on chromosome 17p, and its product is a nuclear phosphoprotein. The p53 protein has been identified as a transcription factor with sequence-specific DNAbinding properties and an ability to regulate entry into S phase of the cell cycle (/ ,4,5) . The p53 protein has also been shown to influence the induction of apoptosis in malignant cells (6) .
In breast cancer, research has focused on patients with primary, node-negative breast disease, and alterations in the p53 gene have been associated with worse prognosis (7) (8) (9) .
Previous studies (8, (10) (11) (12) (13) (14) (15) (16) (17) (18) ) evaluating p53 status in cancer have used single-stranded conformation polymorphism analysis (SSCP), DNA sequence analysis, or immunohistochemistry (IHC). Detection of p53 mutations by IHC is based on the ac-cumulation of mutant p53 protein in cells due to conformational changes in the p53 polypeptide that result in increased stability (4, 19) . Wild-type p53 protein has a short half-life and is not usually detected by IHC. However, the accuracy of detecting p53 mutations by IHC has been questioned. A recent study (20) comparing five different anti-p53 antibodies revealed positive IHC staining in 18%-35% of the tumors examined if individual antibodies were used and in 45% of the tumors if a cocktail of two of the antibodies (i.e., antibody 240 and Pab 1801) was used. Even if the true mutation status of the p53 gene is not revealed by IHC, it has been suggested that this methodologic approach may provide information more reflective of the functional status of the p53 protein than that provided by molecular biological techniques such as DNA sequencing (21) and, therefore, might be more effective in defining patients with poor prognosis.
In this study, we compared the prognostic value of screening for p53 gene mutations in breast cancer specimens using IHC (employing the monoclonal antibody Pab 1801) with that of complementary DNA (cDNA)-based sequence analysis of the complete p53 coding region. The cDNA sequences used in this study were determined as part of an effort to evaluate p53 gene status in the primary tumors of 316 patients with breast cancer in relation to adjuvant therapy and prognosis (22) .
Materials and Methods

Study Materials and Patient Population
Tumor material from 316 consecutive patients operated on for primary invasive breast cancer in Uppsala County (Sweden) from January 1, 1987, through December 31, 1989 , was used in this study. The tumors were collected at the Department of Pathology, University of Uppsala, Akademiska sjukhuset, Sweden. This department contained the only laboratory for histopathology in Uppsala County during the study period. All breast cancer samples were sent directly, unfixed and fresh, from the operation theater to the Department of Pathology.
Patient age at diagnosis ranged from 28 to 94 years, with a median age of 63 years. Tumor sizes ranged from 2 to 130 mm, with a median size of 20 mm. Lymph node metastases were detected in 97 (31 %) of the 316 patients.
Of the 316 patients, 111 were diagnosed via a mammography screening program initiated in 1988, which invited all women in Uppsala County aged 40-74 years to participate.
Patient records were reviewed with regard to relapse information and date of death without knowledge of the p53 status of the tumors. Details about primary adjuvant therapy, including radiotherapy, and relapse therapy were also recorded. All fatal outcomes were studied, and causes of death were divided into three categories: 1) death caused by breast cancer, 2) death with signs of active breast cancer, and 3) death from other causes without signs of relapse. These clinical data were analyzed together with prospectively recorded data on lymph node status and p53 data from IHC and cDNA sequencing.
Therapy and Clinical Follow-up
Locoregional therapy. Primary surgical therapy consisted of either sector resection or modified radical mastectomy; in both instances, this was combined with axillary lymph node dissection. Axillary lymph node status information is missing for 13 patients for whom nodal exploration was not performed because of high age or the presence of other serious concomitant disease.
Patients with lymph node-positive disease or tumors larger than 20 mm in diameter located in the medial or central area of the breast received locoregional radiotherapy, except for 19 women who did not receive such therapy because of high age or the presence of concomitant or metastatic disease. Patients who underwent sector resection were routinely given radiotherapy, except for those who participated in two randomized studies exploring the efficacy of postoperative radiotherapy. [One of these studies has been published (25) ].
Systemic adjuvant therapy. Systemic adjuvant therapy was offered routinely to all patients with lymph node-positive disease. Premenopausal women received intravenous adjuvant polychemotherapy consisting primarily of six to nine courses of intravenous cyclophosphamide. methotrexate. and 5-fluorouracil. When radiotherapy was given concurrently, only cyclophosphamide was administered. Tamoxifen was given to postmenopausal women with lymph nodepositive disease. Tamoxifen was also given to women with stage II tumors who were lymph node negative as part of a randomized trial. Individualized therapeutic strategies were used for patients with primary inoperable disease or metastatic disease.
Follow-up. All patients treated for breast cancer in Uppsala County were seen on a regular outpatient basis at increasing intervals of time each year for at least 5 years; after 5 years, they were seen on a yearly basis until 10 years of follow-up had been completed. A few patients were followed at institutions other than the University of Uppsala; they were referred back to the University of Uppsala (Department of Oncology) on relapse, since this institution has the only clinic for oncology in Uppsala County. The routine follow-up evaluation consisted of a clinical examination. Blood tests and x-ray procedures were performed when indicated. Women aged 40-74 years had mammography checkups through the screening program.
Handling of Tumor Material
Each freshly isolated tumor was divided into two equal portions by use of a disposable scalpel. Slices were taken from the outer, viable, cellular region of one half and frozen in isopentane for later DNA analysis and sequencing and for estrogen-and progesterone-receptor determinations. Corresponding slices from the other half were prepared for histopathologic examination. The part of the tumor that was frozen was stored at -70 °C until analysis.
Sequence-Based Analysis of p53 Status
RNA preparation and isolation. A 1.5-mL polypropylene microcentrifuge tube containing 300 uL of extraction solution (RNAzole, Cinna Biotec Inc, Houston, TX) was placed on wet ice. A section of frozen tumor specimen (5x2 x 2 mm) to be analyzed was removed with the aid of a disposable scalpel. During this procedure, care was taken to avoid thawing of the specimen to prevent RNA degradation. Such precaution was essential if repeated RNA preparation proved to be necessary. The excised tumor section was placed in the microcentrifuge tube, and it was pressed and squeezed against the walls of the tube with a disposable micropestle (Bergman and Beving, Stockholm, Sweden). Five hundred microliters of RNAzole and 80 uL of a mixture of chloroform and isoamyl alcohol (in the proportions of 24:1) were added to the tube. The contents of the tube were then mixed for 10 seconds using a vortex mixer, and the tube was returned to wet ice for 5 minutes to allow RNA to phase-separate from tissue and other cellular components. Subsequently, the tube was spun in a microcentrifuge for 10 minutes (at 14 000,?), and 350 uL of the aqueous, upper phase was recovered and transferred to a new tube that contained 350 uL of isopropanol. After brief vortex mixing, the new tube was placed on wet ice for 30 minutes and then subjected to microcentrifugation at 14 OOOg for 20 minutes. The supernatant was discarded, and the pelleted RNA was washed twice with 70% ethanol, dried briefly, and finally dissolved in 50 uL of diethyl pyrocarbonate-treated water and 1 uL of RNA guard (25 U: Pharmacia Biotech AB, Uppsala, Sweden).
cDNA synthesis. The RNA samples were heat denatured at 90 °C for 3 minutes, followed by chilling on wet ice for 3 minutes. To prepare a cDNA reaction mixture. 25 uL of a given RNA sample was transferred to a microcentrifuge tube containing 10 uL of Moloney murine leukemia virus reverse transcriptase (200 U, Pharmacia Biotech AB), 2.5 uL of RNA guard (62.5 U). 37. to yield a final volume of 75 uL. The cDNA reaction mixture was incubated at 37 °C for 1 hour, and the reaction products were heat-denatured at 90 °C for 3 minutes and stored at -20 °C.
Polymerase chain reaction (PCR). Five microliters of lOx PCR II buffer (Perkin-Elmer AB. Sundbyberg. Sweden), 5 pmol each of the 5' PCR primer and the 3' PCR primer (one of them being biotinylated). 1.2 |iL of 25 m/W MgCl, (Perkin-Elmer AB). 28 uL of distilled H,O. and 0.8 nL of Taq polymerase (4 U) (Ampli Taq. Perkin-Elmer AB) were mixed together in individual 0.2-mL PCR tubes (Perkin-Elmer AB). Five microliters of a given cDNA preparation or negative control template was added to specified tubes, yielding total PCR reaction volumes of 50 uL. The reaction mixtures were incubated in a Perkin Elmer 9600 PCR machine programmed to carry out 38 temperature cycles with the following profile: 94 °C, 15 seconds: 58 °C. 30 seconds: and 72 'C. 45 seconds. A 5-minute incubation at 72 °C was performed at the conclusion of the thermocycling program, followed by incubation at 4 °C.
Primers. PCR and DNA sequencing primers were synthesized based on the cDNA sequence of p53 messenger RNA. PCR primers were prepared by Custom Design Oligonucleotides (Pharmacia Biotech AB). Four sets of primers were used to cover the complete protein coding region of the p53 cDNA.
PCR primers (B = biotin-labeled). Agarose gel electrophoresis and quality control. To control for contamination of PCR products that might have originated during the steps preceding DNA sequencing, we included negative control samples for both the RNA isolation and the cDNA preparation steps. The negative controls consisted of not adding tissue to RNA extraction tubes and not adding RNA to cDNA-reaction mixtures. The presence of amplified DNA in negative-control sample tubes was taken as an indication that all samples might be contaminated and that the corresponding batch of samples had to be discarded.
The purity, quality, and quantity of amplified DNA from specimens and from controls were evaluated by subjecting 5-|iL aliquots of the relevant PCR products to electrophoresis in 1% agarose gels containing 5 \igJmL ethidium bromide. The 100 base-pair ladder (0.2 (ig; Pharmacia Biotech AB) was used in the gels as a reference standard.
Solid-phase DNA sequencing on combs. Sequencing reactions were performed as described by Lagerkvist et al. (24) with the use of streptavidincoupled Sepharose HP (AutoLoad, Pharmacia Biotech AB) attached to the teeth of plastic combs (solid-phase sequencing combs).
Forty microliters of a PCR product was transferred to a "4-teeth well" containing 80 uL of capture buffer (10 mM Tris-HCI [pH 7.5], 1 mM EDTA, and 2.0 M NaCl). The liquid was carefully mixed by pipetting (avoiding the generation of air bubbles), and a solid-phase sequencing comb was immersed in the resulting mixture. PCR products were captured by the comb during an incubation that lasted at least 60 minutes at room temperature. This incubation was interrupted only by occasional raising and dipping of the comb to improve PCR product capture (24) .
The comb was then moved to a second "4-teeth well" containing 100 |iL of 0.1 M NaOH and incubated at room temperature for 5 minutes. Subsequently, the comb was washed once with 0.1 M NaOH, once with TE buffer (10 mM Tris-HCI [pH 7.5] and 1 mM EDTA), and once with ultra-pure distilled H,O. One hundred four microliters of distilled H,O, 12 uL of lOx concentrated annealing buffer (AutoRead kit, Pharmacia Biotech AB), and 4 uL of a 1 pmol/mL stock solution of fluorescein-labeled sequencing primer were mixed in a third "4-teeth well," followed by insertion of the comb. This annealing mixture, with the comb immersed in it, was heated at 55 °C for 5 minutes and then placed at room temperature for at least 10 more minutes.
Twenty microliters of sequencing reaction mixture (containing 2 uL of lOx concentrated annealing buffer, 1 nL of extension buffer [AutoRead kit, Pharmacia Biotech AB]. 4 uL of d/ddNTP mixture, 12 nL of distilled H 2 O, and I p.L of T7 DNA polymerase [2 U] [diluted in enzyme dilution buffer; AutoRead kit, Pharmacia Biotech AB1) were dispensed into individual "1-tooth wells" just prior to insertion of the comb. The comb was incubated in the wells for 5 minutes at 37 °C, and the entire well assembly (with the comb still inserted) was placed finally on wet ice.
The sample wells of an automated laser fluorescence (ALF; Pharmacia Biotech AB)-sequencing gel (containing 6% polyacrylamide and 7 M urea) were rinsed with 1 x TBE buffer (100 mM Tris. 90 mM boric acid, and I mM EDTA [pH 8.3]), prewarmed to 45 °C, and loaded with 15 |iL of 100% formamide STOP solution (AutoRead kit, Pharmacia Biotech AB). The comb was removed from the sequencing-reaction wells and inserted into the wells of the ALF-sequencing gel for 10 minutes. The comb was then carefully removed from the gel apparatus, and ALF electrophoresis was initiated.
Sequencing evaluation and verification. Evaluation of p53 sequences was performed with the aid of a newly developed software program, Sequence Evaluator (Pharmacia Biotech AB), version 0.16. which compares the wild-type sequence of a gene with sequences obtained from sample analysis.
All mutations were confirmed by reamplifying the relevant cDNAs and sequencing the new PCR products. If a mutation was identified in a region contained within the overlapping portion of two cDNA segments, its existence was further verified by analyzing amplification products from the neighboring cDNA segment.
Immunohistochemical Analysis of p53 Status
Paraffin-embedded tumor sections on silane-coated slides (Eire Scientific Co., Porthmouth, Philadelphia. PA) were dewaxed in xylene and rehydrated in ethanol and distilled water. Pretreatment in a microwave oven at 750 W (three times for 5 minutes each) enhanced p53 antigen accessibility to antibodies. The mouse monoclonal antibody cl 1801 (12) (Biozac AB, Jarfalla, Sweden), which recognizes both wild-type and mutant forms of p53, was used at a dilution of 1:100.
lmmunostaining was performed in a Ventana ES Automated Immunohistochemistry Instrument (Annex, Helsinki, Finland). We used the manufacturer's diaminobenzidine (DAB) detection kit that includes biotin-labeled secondary antibodies directed against mouse immunoglobulins, avidin-labeled horseradish peroxidase, and DAB as the localization reagents. Negative control IHC reactions were performed by omitting the primary antibody.
Positive p53 IHC staining is seen in the nucleus of cancer cells. In our primary IHC analysis, positive p53 staining in any percentage of cancer cells was considered to be positive.
In a secondary IHC analysis, IHC-positive samples were subclassified with regard to immunostaining intensity and extent according to graded scales that ranged from 1 to 3. For intensity of staining, 1 represented weakly positive tumor cells and 3 represented strongly positive cells. For extent of staining, I denoted samples in which less than one third of the tumor cells had positive staining, 2 signified those with positive staining in one third to two thirds of the tumor cells, and 3 denoted those with more than two-thirds positive staining. The results obtained with the two scales were multiplied against each other, yielding a single scale with steps of 1, 2, 3, 4, 6, and 9, where I and 2 were considered to be low staining, 3 and 4 were considered to be medium staining, and 6 and 9 were considered to be high staining. This classification system is derived from that described by Busch et al. (25) . All slides were viewed and judged independently by two pathologists (A. Lindgren and H. Nordgren) according to this multiplied scale at different times without knowledge of clinical outcome and p53 mutation status.
Statistical Methods
Survival probabilities for overall, breast cancer-corrected, and relapse-free survivals were estimated by use of the Kaplan-Meier method, and the equality of survival curves for different subgroups was evaluated by use of the logrank method. All P values are estimated from two-sided statistical tests. Relative hazards of dying of breast cancer were estimated by use of Cox's proportional hazards models. In the multivariate models, age at diagnosis, tumor size, estrogen-and progesterone-receptor status, and S phase proportion were taken into consideration. Hormone-receptor status was dichotomized as negative versus positive variables (cutoff point, 0.1 fmol/ug DNA) and S phase as high versus low variables (cutoff points, 1% for diploid and 12% for aneuploid tumors, respectively). In breast cancer-corrected survival, death from breast cancer was considered to be the event of interest; all other deaths were treated as censoring 
Results
Clinical Outcome
Of the 316 patients included in the study, 48 died of breast cancer, five died with breast cancer present, and 21 died of unrelated causes. For seven patients, we lack information about the cause of death. The median follow-up in this study was 57 months, with a maximum follow-up of 87 months.
Mutations Detected and IHC Results
Alterations in the p53 gene were detected by means of the cDNA-based sequencing method in tumors from 69 (22%) of the 316 patients. p53 mutations were found throughout the entire protein coding region of the gene. Twenty-nine p53 mutations were detected in patients whose tumors had metastasized to axillary lymph nodes, 37 mutations were found in node-negative patients, and three mutations were detected in patients with unknown primary lymph node status. We identified 45 missense (simple point) mutations, seven nonsense mutations (creating premature stop codons), five in-frame deletions, eight out-offrame deletions, one in-frame insertion, and three out-of-frame insertions (Table 1 ; Fig. 1 ). Thirty-one (45%) of the 69 mutations were located in evolutionarily conserved regions of p53 ( Fig. 1) . From four tumors (1.3% of the total), we were unable to obtain sequence information; from three others (1% of the total), we lack immunohistochemical data (Table 2) . Thus, tumors from 309 patients were available for this comparative study. Since follow-up data were missing for one patient, 308 patients could be included in survival analyses.
Positive IHC (suggesting p53 mutation) was demonstrated in tumors from 64 (20%) of the 316 patients. Twenty-three (33%) of the sequence-positive patients (i.e., proven to have p53 mutations) were negative by IHC, whereas 19 (30%) of the IHCpositive patients were sequence negative ( Table 2) . Negative immunohistochemical reactions were noticed in all six tumors with mutations that created premature stop codons and in 11 (85%) of 13 tumors with deletions (Table 1; Fig. 1 ). Positive immunohistochemical reactions were seen in 40 (89%) of 45 tumors with point mutations (Table 1; Fig. 1 ).
Our primary method of IHC classification (see "Materials and Methods" section) was used to generate the IHC data described above. There was complete concordance between the two pathologists regarding the assessment of negative and positive immunohistochemical reactions with this method.
When the 64 immunohistochemically positive tumors were subclassified according to the 6-graded (1-9) scale (i.e., our secondary IHC analytical method; see "Materials and Methods" section), the pathologists agreed in 75% of the cases. With this more complex grading system, 12.5% of the tumors fell into different low-, medium-, and high-staining groups as judged by the two independent investigators, whereas assessments regarding low-staining versus medium-to high-staining were divergent in only 7.8% of cases. Within the low-staining group, however, there was a major discrepancy regarding subclasses 1 and 2, and there was only 53.8% agreement with respect to the proposed class-1 tumors.
Comparison of Survival Data
We analyzed the patient data with regard to survival and p53 mutation status as determined by IHC and by cDNA-based sequencing. Survival was illustrated as relapse-free survival (RFS; 304 patients), breast cancer-corrected survival (BCCS; 308 patients), and overall survival (OS; 308 patients).
IHC and survival. According to IHC, there was a trend of reduced OS for patients with p53-positive tumors compared with those having p53-negative tumors, but it did not reach statistical significance (P = .2) ( Table 3) . No statistically significant differences could be detected in any of the survival parameters between p53-positive and p53-negative tumors according to IHC (Table 3) .
cDNA sequencing and survival. Highly significant differences in survival were seen between patients with sequencingpositive and sequencing-negative tumors, with worse prognosis for those with positive tumors. The 5-year OS frequency was 78% in the mutation-negative group as opposed to 55% for those with p53 mutations (P -.0003). Similar statistically significant differences were seen for RFS and BCCS (Table 3) .
Positive IHC with or without positive cDNA sequencing. In 61 women with positive IHC, we saw statistically significant differences in RFS between those with sequencing-positive tumors and those with sequencing-negative tumors (Fig. 2, top  panel) . The 5-year RFS in this IHC-positive patient population was 86% for the sequencing-negative group and 56% for the sequencing-positive group (P = .02; Fig. 2, top panel) . Differences in BCCS between sequencing-positive and sequencing-negative patients with positive IHC were also statistically significant (62 patients evaluated, data not shown). None of 19 patients with IHC-positive tumors but negative-sequencing results had died of breast cancer (BCCS) at 60 months' follow-up, whereas 10 of the 43 patients with positive-sequencing results had died at 60 months of follow-up (P = .03). There was a trend in the same direction for OS, but it was not statistically significant (Fig. 3 , top panel). Negative IHC with or without positive cDNA sequencing. In the 246 evaluable patients with negative IHC, there were statistically significant differences in all three survival categories, including RFS (243 patients; Fig. 2, bottom panel) , between the sequencing-negative and sequencing-positive cases, with worse prognosis for patients with positive sequencing results. The most marked difference was seen in the OS comparison, where the 5-year survival frequency was 78% in the sequencing-negative group as opposed to 48% in the sequencingpositive group (P -.002; Fig. 3, bottom panel) .
Positive cDNA sequencing with or without positive IHC. For the women with sequence-determined p53 mutations, there were no significant differences in any of the survival categories between the IHC-positive and the IHC-negative groups (Fig. 2,  left panel; Fig. 3, left panel) .
Negative cDNA sequencing with or without positive IHC. For the cDNA-based sequencing-negative patients, no significant differences in survival were observed between the IHCpositive and the IHC-negative groups. There was even a trend .2 *RFS = relapse-free survival; BCCS = breast cancer-corrected survival; OS = overall survival; n = No. of patients; positive = mutation positive by sequencing or positive staining by IHC; negative = wild-type p53 or negative staining by IHC; cDNA = complementary DNA. All P values according to the logrank test.
for better survival in the group with positive IHC reactions (Fig.  2, right panel; Fig. 3, right panel) .
Survival Analysis When IHC Low-Staining Tumors Were Classified as p53 Negative
In our primary IHC analysis of p53 status and survival, which did not indicate any statistically significant differences in survival between IHC-positive and IHC-negative groups, all 64 tumors with positive IHC staining were considered to be p53 positive (i.e., mutant). We then reanalyzed the data obtained from each of the pathologists, considering the IHC-positive subclasses 1-2 (i.e., the "low-staining group" in the more complex grading system, see "Materials and Methods" section) as negative cases. In comparison with our primary classification, this secondary classification improved all P values for differences in RFS, BCCS, and OS between IHC-positive and IHC-negative tumors. The best P values were seen for OS and, according to data from one of the pathologists, the difference in OS became statistically significant (Table 4 ). The P values obtained from the other pathologist's review were also improved relative to those from the primary analysis, but none of the values reached statistical significance. However, it is important to note that with this modification in IHC classification the number of positive cases was reduced to 36 and 39, as judged by the two pathologists, respectively (Table 4) .
Proportional Hazards Models
Proportional hazards models were tested to investigate whether prognostic information generated by cDNA sequencing and IHC was positively or negatively confounded by other commonly used prognostic markers. The relative hazards for p53 alterations were of the same magnitude in both the univariate and multivariate models ( Table 5 ). The relative hazards for positive cDNA sequencing data were higher than those for positive IHC data, with confidence intervals indicating an independent effect; the confidence intervals for the immunohistochemical data clearly included 1.0. *See "Materials and Methods" section for details. tlHC = immunohistochemistry; cDNA = complementary DNA; sequencing = cDNA sequencing; p53 status positive = mutation by sequencing or positive IHC; p53 status negative = wild-type p53 by sequencing or negative IHC; IHC I = IHC results by pathologist I (A. Lindgren) after modification with subclasses I and 2 considered to be negative IHC; IHC 2 = IHC results by pathologist 2 (H. Nordgren) after modification with subclasses 1 and 2 considered to be negative IHC. All P values according to the logrank test. 
Factor
Discussion
This study differs from most other studies of p53 status and cancer in that the patient population, consisting of 316 women with primary breast cancer, was derived from a populationbased cohort. The breast cancer specimens were examined by IHC with use of the monoclonal antibody Pab 1801, an antibody whose use on paraffin-embedded tumor samples is now widely accepted (7, 16, (26) (27) (28) (29) . The specimens were also analyzed by use of a cDNA-sequencing strategy in which all exons of the p53 gene were evaluated. Our cDNA sequencing approach stands in contrast with previous investigations of p53 gene alterations in human breast cancer, which have focused primarily on sequence changes in exons 5, 6, 7, and 8.
We observed that 23 breast cancers with p53 alterations detected by cDNA-based sequencing failed to generate positive IHC reactions with Pab 1801; 19 tumors were negative for mutation by cDNA sequencing but were positive by IHC. The lack of concordance between results obtained with these two methods may indicate that they measure different aspects of p53. An ideal method should be one that gives the best prognostic information in relation to currently used therapeutic approaches and the best delineation of the patient groups studied. Our data clearly demonstrate that the cDNA sequencing method is superior in these regards. Our finding should be of importance, since most published p53 status determinations have been based on IHC analyses. In view of the discrepancy between results obtained with the two methods, we will now discuss possible explanations for false-positive and false-negative results with each method.
The prognostic information generated by IHC-and cDNA sequence-based determinations of p53 status gave us reason to believe that IHC might generate false-positive as well as falsenegative results. This was suggested by the observation that the patient group with negative cDNA sequencing data (i.e., their tumors had wild-type p53 genes) but positive IHC results did not seem to have a significantly worse prognosis than the corresponding IHC-negative group. The suspicion of false-positive IHC results is supported when considering the IHC-positive group, where comparison of the sequencing-positive and sequencing-negative patients showed significantly better survival for the patients with negative sequencing data. There are also signs of false-negative cases of IHC in the IHC-negative patient group, where significantly worse prognosis was observed for patients with positive cDNA sequencing data compared with those with negative sequencing data. Similarly, in the cDNA sequencing-positive group, no difference in prognosis was seen between the IHC-positive and the IHC-negative patients, supporting our conclusions.
False-negative IHC results may be generated as a consequence of premature stop codons and gross deletions in the p53 gene, since such alterations could lead to a cessation of protein synthesis and render the detection of mutations by IHC impossible. Our results are consistent with this hypothesis, since all six samples with premature stop codons showed negative IHC reactions. Similarly, 11 of 13 tumors with deletions and one of three tumors with insertions were negative by IHC. Thus, 18 of the 23 evaluable samples with aberrations detected by cDNA sequencing but IHC negative had deletions, insertions, and premature stop codons. In contrast, only four of 44 samples with positive IHC had mutations of these types (F<.001).
Another possible explanation for negative IHC results in sequencing-positive tumors may be that the genetic alterations caused changes in or disappearance of the epitope recognized by Pab 1801, which is located between amino acids 40 and 65 (50). However, few of the alterations that we identified are located in this region. Furthermore, most of the p53 proteins truncated as a consequence of premature stop codons should still contain the Pab 1801 epitope. It has been suggested that missense mutations (19, 31) , as well as deletions, insertions (32) , and premature stop codons (33) , might produce conformational changes in the p53 polypeptide that interfere with recognition of the epitope for Pab 1801. In addition, Ohuc et al. (33) have proposed that truncation of the carboxyl terminus of p53 might reduce the stability of the mutated protein because of the loss of several important functional domains, such as the DNA binding domain, the nuclear localization signals, and the oligomerization domain. The accumulation of p53 protein would thus fail to occur, making detection by IHC impossible. In this study, all deletions and stop codon mutations identified were located downstream of codons that define the Pab 1801 epitope, supporting these theories. It is also possible that certain point mutations may not be able to stabilize the p53 protein sufficiently to be detectable by IHC (21).
The theoretical basis for the determination of p53 status by IHC is that mutant p53 protein exhibits a longer half-life than wild-type p53, which results in the accumulation of p53 protein in transformed cells (4, 19) . However, it is possible that the accumulation of p53 in tumor cells may, in some cases, indicate the existence of a regulatory defect rather than mutations in the protein-coding sequence of the gene. Several investigators (34, 35) have found discrepancies between p53 protein expression and mutation status. In some cases, weak immunostaining could also represent normal cell cycle fluctuations in p53 protein levels, as indicated in a few reports (36, 37) . In our study, 13 of 19 tumors that were positive for p53 by IHC and had wildtype p53 cDNA sequences displayed weakly positive IHC signals only. For the 243 patients with negative cDNA sequencing data, we observed a nonsignificant trend of better survival for those with IHC-positive tumors relative to those with IHC-negative tumors. One may speculate that the improved survival could be due, in part, to increased amounts of normal p53 protein, which might facilitate apoptosis induced by tamoxifen therapy, chemotherapy, or radiotherapy.
Can IHC analysis be refined to increase its resolving power? It has been shown that strong immunostaining is associated with the presence of p53 gene alterations detected by molecular biological methods to a greater extent than is low-grade IHC staining (38) . It has also been demonstrated that IHC with Pab 1801 generates better prognostic information when considered as a continuous variable than as a dichotomous variable (8) .
With these thoughts in mind, we made an additional analysis in which the IHC low-staining group (i.e., subclasses 1 and 2) were considered to be negative. This approach improved the significance of the P values obtained in all three measured survival categories. One of the P values, on the basis of one pathologist's data, became statistically significant (OS, IHC positive versus IHC negative), whereas in our primary analysis (where all positive reactions were considered as p53-positive cases) none of the P values were significant. This result may indicate that the diagnostic specificity of IHC is impaired by technical limitations and/or more fundamental biological properties of the p53 regulatory system. To achieve a similar level of significance as that obtained with the use of sequencing data, the number of positive cases was substantially reduced, thus lowering the sensitivity of the method and increasing the risk of false-negative cases.
Having analyzed the IHC data with regard to false-negative and false-positive results, we will now discuss the sequencebased analysis in the same respect. False-positive sequencing results may occur as a consequence of contamination of samples during processing. In this study, we identified p53 gene mutations in 69 cases. Most of these alterations were found in 49 different codons resulting in 55 different mutations. Seven of the 14 remaining mutations were located in mutational "hot spots" reported by others (59). Given this diversity, we have no reason to suspect false-positive sequencing data in our study. This conclusion is further strengthened by the finding that none of the negative cDNA/PCR controls yielded any amplification products, indicating that the integrity of the tumor isolates was maintained.
False-negative sequencing reactions may, on the other hand, represent a greater risk. Theoretically, this could happen if the tumor samples used for the analysis contained relatively few malignant cells in relation to normal cells, which could cause the wild-type sequence to "drown out" the mutant sequence. The manner in which the tumor material was isolated in this study should have minimized such a risk. cDNA sequencing might also fail to detect a mutation if the alteration is located in a position disadvantageous for proper primer (cDNA or PCR) binding. This risk would be greatest at the extreme ends of the p53 coding region with our approach.
Taken together, our data indicate that direct cDNA sequencebased analysis of p53 status is superior to IHC in determining prognosis in breast cancer. If complete sequencing of the p53 coding region by use of the present method is taken as the gold standard, false-positive as well as false-negative results can occur with IHC. In terms of using p53 status in clinical decision making with regard to adjuvant therapy, both false positives and false negatives would pose problems.
